8-K Announcements
6Material company update
Mar 23, 2026·SEC
Material company update
Mar 9, 2026·SEC
Material company update
Feb 3, 2026·SEC
Mesa Laboratories, Inc.(MLAB)Earnings, Financials & Key Ratios
MLAB•NASDAQ
$105.96
$585M mkt cap·Price updated May 6, 2026
SectorTechnologyIndustryTech Hardware & EquipmentSub-IndustryTest, Measurement and Inspection Equipment
AboutMesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.Show more
- Revenue$241M+11.5%
- EBITDA$41M+117.0%
- Net Income-$2M+99.2%
- EPS (Diluted)-0.36+99.2%
- Gross Margin62.61%+1.6%
- EBITDA Margin16.96%+115.2%
- Operating Margin6.78%+105.4%
- Net Margin-0.82%+99.3%
- ROE-1.29%+98.6%
- ROIC3.7%+108.1%
- Debt/Equity1.14-28.6%
- Interest Coverage1.38+102.9%
MLAB Key Insights
Mesa Laboratories, Inc. (MLAB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 17.6% free cash flow margin
- ✓Strong 5Y sales CAGR of 15.4%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MLAB Price & Volume
Mesa Laboratories, Inc. (MLAB) stock price & volume — 10-year historical chart
Loading chart...
MLAB Growth Metrics
Mesa Laboratories, Inc. (MLAB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years12.95%
5 Years15.41%
3 Years9.34%
TTM4.12%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM101.5%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM101.38%
Return on Capital
10 Years-0.83%
5 Years-8.92%
3 Years-15.97%
Last Year4.86%
MLAB Recent Earnings
Mesa Laboratories, Inc. (MLAB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 5/12 qtrs (42%)
Q1 2026Latest
Feb 3, 2026EPS
$3.07
Est $1.40
+119.3%
Revenue
$65M
Est $63M
+3.0%
Q4 2025
Nov 6, 2025EPS
$1.76
Est $1.56
+12.8%
Revenue
$61M
Est $61M
-0.5%
Q3 2025
Aug 5, 2025EPS
$2.32
Est $2.46
-5.7%
Revenue
$60M
Est $60M
-1.4%
Q2 2025
May 28, 2025EPS
$2.23
Est $2.75
-18.9%
Revenue
$62M
Est $62M
+0.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 3, 2026 | $3.07vs $1.40+119.3% | $65Mvs $63M+3.0% |
| Q4 2025 | Nov 6, 2025 | $1.76vs $1.56+12.8% | $61Mvs $61M-0.5% |
| Q3 2025 | Aug 5, 2025 | $2.32vs $2.46-5.7% | $60Mvs $60M-1.4% |
| Q2 2025 | May 28, 2025 | $2.23vs $2.75-18.9% | $62Mvs $62M+0.4% |
Based on last 12 quarters of dataView full earnings history →
MLAB Peer Comparison
Mesa Laboratories, Inc. (MLAB) competitors in Test, Measurement and Inspection Equipment — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NEOG | 2B | 9.18 | -1.83 | -3.2% | -68.47% | -28.64% | 0.44 | |
 LFUS | 11.11B | 441.67 | -152.30 | 8.92% | -1.61% | -1.57% | 0.39 | |
 NOVT | 4.95B | 138.90 | 94.49 | 3.3% | 5.49% | 4.1% | 0.26 | |
 RGEN | 7.09B | 125.76 | 146.23 | 16.36% | 6.73% | 2.46% | 0.33 | |
 TRMB | 15.02B | 63.42 | 36.24 | -2.61% | 12.37% | 7.95% | 0.24 | |
 BIO | 6.99B | 259.02 | 9.29 | 0.65% | 6.52% | 2.4% | 0.21 | |
 IDXX | 46.12B | 579.23 | 44.28 | 10.42% | 24.63% | 70.87% | 0.67 | |
 BRKR | 6.44B | 42.30 | -282 | 2.08% | -0.75% | -1.11% | 0.81 |
Compare MLAB vs Peers
Mesa Laboratories, Inc. (MLAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MLAB Income Statement
Mesa Laboratories, Inc. (MLAB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 93.67M | 96.18M | 103.14M | 117.69M | 133.94M | 184.34M | 219.08M | 216.19M | 240.98M | 247.54M |
| Revenue Growth % | 10.64% | 2.68% | 7.23% | 14.11% | 13.81% | 37.63% | 18.85% | -1.32% | 11.47% | 4.12% |
| Cost of Goods Sold | 40.43M | 41.56M | 42.22M | 52.33M | 46.92M | 75.25M | 85.39M | 82.94M | 90.11M | 97.51M |
| COGS % of Revenue | 43.16% | 43.21% | 40.94% | 44.46% | 35.03% | 40.82% | 38.98% | 38.36% | 37.39% | - |
| Gross Profit | 53.24M▲ 0% | 54.62M▲ 2.6% | 60.92M▲ 11.5% | 65.36M▲ 7.3% | 87.01M▲ 33.1% | 109.09M▲ 25.4% | 133.69M▲ 22.6% | 133.25M▼ 0.3% | 150.87M▲ 13.2% | 150.03M▲ 0% |
| Gross Margin % | 56.84% | 56.79% | 59.06% | 55.54% | 64.97% | 59.18% | 61.02% | 61.64% | 62.61% | 60.61% |
| Gross Profit Growth % | 3.55% | 2.59% | 11.53% | 7.3% | 33.13% | 25.37% | 22.55% | -0.33% | 13.22% | - |
| Operating Expenses | 36.93M | 38.62M | 43.06M | 57.44M | 74.66M | 104.39M | 130.37M | 405.32M | 134.53M | 132.8M |
| OpEx % of Revenue | 39.42% | 40.15% | 41.75% | 48.81% | 55.74% | 56.63% | 59.51% | 187.49% | 55.83% | - |
| Selling, General & Admin | 32.77M | 35.08M | 39.55M | 51.08M | 64.27M | 88.62M | 109.88M | 111.49M | 115.02M | 117.09M |
| SG&A % of Revenue | 34.99% | 36.47% | 38.35% | 43.41% | 47.98% | 48.08% | 50.16% | 51.57% | 47.73% | - |
| Research & Development | 4.16M | 3.54M | 3.51M | 6.36M | 10.39M | 15.77M | 20.49M | 19.3M | 19.52M | 20.16M |
| R&D % of Revenue | 4.44% | 3.68% | 3.4% | 5.4% | 7.76% | 8.55% | 9.35% | 8.93% | 8.1% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 274.53M | 0 | -1000K |
| Operating Income | 16.31M▲ 0% | 2.18M▼ 86.6% | 9.78M▲ 348.1% | 7.92M▼ 19.0% | 12.36M▲ 56.0% | 4.7M▼ 62.0% | 3.32M▼ 29.4% | -272.07M▼ 8295.0% | 16.34M▲ 106.0% | 17.23M▲ 0% |
| Operating Margin % | 17.42% | 2.27% | 9.48% | 6.73% | 9.23% | 2.55% | 1.52% | -125.85% | 6.78% | 6.96% |
| Operating Income Growth % | -0.06% | -86.62% | 348.05% | -19% | 55.98% | -61.95% | -29.39% | -8295.03% | 106% | - |
| EBITDA | 25.05M | 11.65M | 19.25M | 20.91M | 30.02M | 29.77M | 36.45M | -240.5M | 40.86M | 36.53M |
| EBITDA Margin % | 26.74% | 12.12% | 18.66% | 17.77% | 22.41% | 16.15% | 16.64% | -111.25% | 16.96% | 14.76% |
| EBITDA Growth % | 6.61% | -53.48% | 65.18% | 8.64% | 43.54% | -0.83% | 22.45% | -759.74% | 116.99% | 115.67% |
| D&A (Non-Cash Add-back) | 8.74M | 9.47M | 9.47M | 12.99M | 17.66M | 25.07M | 33.13M | 31.57M | 24.53M | 19.3M |
| EBIT | 16.31M | 2.15M | 8.62M | 9.37M | 10.33M | 7.46M | 4.38M | -269.95M | 17.82M | 25.03M |
| Net Interest Income | 0 | -1.85M | -1.72M | -4.54M | -7.92M | -3.88M | -4.77M | -5.7M | -11.86M | -10.62M |
| Interest Income | 0 | 5K | 1.72M | 960K | 107K | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 1.85M | 0 | 5.5M | 8.02M | 3.88M | 4.77M | 5.7M | 11.86M | 10.62M |
| Other Income/Expense | -2.02M | -1.88M | -1.16M | -4.06M | -10.05M | -1.13M | -3.71M | -3.57M | -10.38M | -3.16M |
| Pretax Income | 14.3M▲ 0% | 301K▼ 97.9% | 8.62M▲ 2764.8% | 3.86M▼ 55.2% | 2.3M▼ 40.4% | 3.57M▲ 55.2% | -389K▼ 110.9% | -275.65M▼ 70760.7% | 5.96M▲ 102.2% | 14.07M▲ 0% |
| Pretax Margin % | 15.26% | 0.31% | 8.36% | 3.28% | 1.72% | 1.94% | -0.18% | -127.5% | 2.47% | 5.68% |
| Income Tax | 3.11M | 3.26M | 1.14M | 2.08M | -971K | 1.7M | -1.32M | -21.4M | 7.93M | 10.33M |
| Effective Tax Rate % | 21.78% | 1084.05% | 13.21% | 53.96% | -42.16% | 47.65% | 339.07% | 7.76% | 133.12% | 73.46% |
| Net Income | 11.18M▲ 0% | -2.96M▼ 126.5% | 7.48M▲ 352.7% | 1.78M▼ 76.2% | 3.27M▲ 84.1% | 1.87M▼ 42.9% | 930K▼ 50.3% | -254.25M▼ 27438.3% | -1.97M▲ 99.2% | 3.73M▲ 0% |
| Net Margin % | 11.94% | -3.08% | 7.26% | 1.51% | 2.44% | 1.01% | 0.42% | -117.6% | -0.82% | 1.51% |
| Net Income Growth % | 0.13% | -126.49% | 352.67% | -76.24% | 84.14% | -42.85% | -50.29% | -27438.28% | 99.22% | 101.5% |
| Net Income (Continuing) | 11.18M | -2.96M | 7.48M | 1.78M | 3.27M | 1.87M | 930K | -254.25M | -1.97M | 3.73M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 2.91▲ 0% | -0.79▼ 127.1% | 1.86▲ 335.4% | 0.31▼ 83.3% | 0.64▲ 106.5% | 0.35▼ 45.3% | 0.17▼ 51.4% | -47.20▼ 27864.7% | -0.36▲ 99.2% | 0.67▲ 0% |
| EPS Growth % | -2.02% | -127.15% | 335.44% | -83.33% | 106.45% | -45.31% | -51.43% | -27864.71% | 99.24% | 101.38% |
| EPS (Basic) | 3.04 | -0.79 | 1.95 | 0.32 | 0.66 | 0.36 | 0.17 | -47.20 | -0.36 | - |
| Diluted Shares Outstanding | 3.84M | 3.77M | 4.03M | 4.37M | 5.12M | 5.33M | 5.36M | 5.39M | 5.43M | 5.57M |
| Basic Shares Outstanding | 3.68M | 3.75M | 3.84M | 4.2M | 4.97M | 5.21M | 5.32M | 5.39M | 5.43M | 5.53M |
| Dividend Payout Ratio | 21.06% | - | 32.9% | 153.09% | 96.67% | 178.46% | 366.24% | - | - | - |
MLAB Balance Sheet
Mesa Laboratories, Inc. (MLAB) balance sheet — assets, liabilities & shareholders' equity
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 35.78M | 31.99M | 33.62M | 122.79M | 303.75M | 124.32M | 118.97M | 109.35M | 102.69M | 105.63M |
| Cash & Short-Term Investments | 5.82M | 5.47M | 10.19M | 81.38M | 263.87M | 49.35M | 32.91M | 28.21M | 27.32M | 28.98M |
| Cash Only | 5.82M | 5.47M | 10.19M | 81.38M | 263.87M | 49.35M | 32.91M | 28.21M | 27.32M | 28.98M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 14.32M | 14.3M | 12.52M | 21.13M | 23.79M | 41.22M | 42.55M | 39.05M | 41.97M | 40.23M |
| Days Sales Outstanding | 55.8 | 54.28 | 44.29 | 65.54 | 64.82 | 81.63 | 70.89 | 65.94 | 63.57 | 59.48 |
| Inventory | 13.87M | 9.23M | 6.77M | 14.23M | 11.18M | 24.61M | 34.64M | 32.67M | 25.36M | 26.56M |
| Days Inventory Outstanding | 125.26 | 81.04 | 58.55 | 99.26 | 86.95 | 119.36 | 148.08 | 143.8 | 102.75 | 100.85 |
| Other Current Assets | 587K | 2.21M | 2.55M | 1.91M | 0 | 0 | 4.04M | 3.34M | 2.87M | 9.87M |
| Total Non-Current Assets | 135.95M | 132.11M | 123.14M | 297.41M | 297.73M | 583.05M | 542.86M | 337.44M | 330.66M | 329.22M |
| Property, Plant & Equipment | 26M | 23.59M | 22.23M | 22.07M | 22M | 28.62M | 28.15M | 41.44M | 32.33M | 31.6M |
| Fixed Asset Turnover | 3.60x | 4.08x | 4.64x | 5.33x | 6.09x | 6.44x | 7.78x | 5.22x | 7.45x | 7.77x |
| Goodwill | 72.16M | 65.54M | 66.38M | 141.54M | 160.84M | 291.17M | 286.44M | 180.1M | 181.76M | 189.3M |
| Intangible Assets | 37.79M | 42.85M | 33.22M | 119.87M | 111.74M | 250.12M | 216.81M | 113.75M | 96.88M | 21.75M |
| Long-Term Investments | -113.5M | -108.52M | -246K | -272.87M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 109.95M | 108.52M | 246K | 275.35M | 2.53M | 11.83M | 10.37M | 867K | 18.32M | 210.65M |
| Total Assets | 171.73M▲ 0% | 164.1M▼ 4.4% | 156.77M▼ 4.5% | 420.21M▲ 168.0% | 601.48M▲ 43.1% | 707.37M▲ 17.6% | 661.83M▼ 6.4% | 446.8M▼ 32.5% | 433.35M▼ 3.0% | 434.85M▲ 0% |
| Asset Turnover | 0.55x | 0.59x | 0.66x | 0.28x | 0.22x | 0.26x | 0.33x | 0.48x | 0.56x | 0.57x |
| Asset Growth % | 6.83% | -4.44% | -4.47% | 168.04% | 43.14% | 17.61% | -6.44% | -32.49% | -3.01% | -9.81% |
| Total Current Liabilities | 16.57M | 17.29M | 23.66M | 26.01M | 32.58M | 48.05M | 43.36M | 44.31M | 163.96M | 54.4M |
| Accounts Payable | 2.17M | 2.38M | 2.9M | 3.41M | 4.47M | 7.9M | 6.13M | 6.04M | 5.75M | 5.25M |
| Days Payables Outstanding | 19.57 | 20.9 | 25.05 | 23.77 | 34.79 | 38.31 | 26.22 | 26.59 | 23.28 | 20.92 |
| Short-Term Debt | 1.13M | 1.63M | 2.13M | 0 | 0 | 0 | 0 | 0 | 101.05M | 5.16M |
| Deferred Revenue (Current) | 4.12M | 3.92M | 3.96M | 6.81M | 9.29M | 14.58M | 15.69M | 15.48M | 14.71M | 58.6M |
| Other Current Liabilities | 4.29M | 4.07M | 7.35M | 12.74M | 0 | 0 | 0 | 15.49M | 0 | 29.43M |
| Current Ratio | 2.16x | 1.85x | 1.42x | 4.72x | 9.32x | 2.59x | 2.74x | 2.47x | 0.63x | 0.63x |
| Quick Ratio | 1.32x | 1.32x | 1.13x | 4.17x | 8.98x | 2.07x | 1.94x | 1.73x | 0.47x | 0.47x |
| Cash Conversion Cycle | 161.48 | 114.42 | 77.79 | 141.03 | 116.98 | 162.68 | 192.75 | 183.15 | 143.04 | 139.41 |
| Total Non-Current Liabilities | 57.34M | 47.45M | 21.8M | 174.19M | 162.66M | 265.51M | 224.99M | 257.09M | 109.56M | 193.76M |
| Long-Term Debt | 53.67M | 44.63M | 20.61M | 140.28M | 145.68M | 218.37M | 183.27M | 221.7M | 76.9M | 98.25M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.61M | 0 | 12.66M |
| Deferred Tax Liabilities | 3.55M | 2.62M | 1.08M | 32.55M | 16.27M | 39.22M | 34.03M | 19.78M | 20.18M | 85.24M |
| Other Non-Current Liabilities | 116K | 194K | 105K | 1.36M | 715K | 7.92M | 7.69M | 9M | 12.47M | 97.92M |
| Total Liabilities | 73.91M | 64.74M | 45.46M | 200.19M | 195.25M | 313.57M | 268.35M | 301.4M | 273.52M | 248.16M |
| Total Debt | 54.8M | 46.26M | 22.74M | 141.37M | 146.7M | 221.13M | 186.14M | 231.3M | 181.47M | 103.41M |
| Net Debt | 48.98M | 40.79M | 12.55M | 59.99M | -117.17M | 171.79M | 153.23M | 203.08M | 154.15M | 74.43M |
| Debt / Equity | 0.56x | 0.47x | 0.20x | 0.64x | 0.36x | 0.56x | 0.47x | 1.59x | 1.14x | 1.14x |
| Debt / EBITDA | 2.19x | 3.97x | 1.18x | 6.76x | 4.89x | 7.43x | 5.11x | - | 4.44x | 2.83x |
| Net Debt / EBITDA | 1.96x | 3.50x | 0.65x | 2.87x | -3.90x | 5.77x | 4.20x | - | 3.77x | 3.77x |
| Interest Coverage | - | 1.18x | - | 1.44x | 1.54x | 1.21x | 0.70x | -47.76x | 1.38x | 2.36x |
| Total Equity | 97.82M▲ 0% | 99.36M▲ 1.6% | 111.31M▲ 12.0% | 220.01M▲ 97.7% | 406.23M▲ 84.6% | 393.8M▼ 3.1% | 393.48M▼ 0.1% | 145.39M▼ 63.0% | 159.83M▲ 9.9% | 186.69M▲ 0% |
| Equity Growth % | 15.52% | 1.57% | 12.03% | 97.66% | 84.64% | -3.06% | -0.08% | -63.05% | 9.93% | 55.19% |
| Book Value per Share | 25.45 | 26.36 | 27.60 | 50.33 | 79.28 | 73.81 | 73.40 | 26.99 | 29.44 | 33.55 |
| Total Shareholders' Equity | 97.82M | 99.36M | 111.31M | 220.01M | 406.23M | 393.8M | 393.48M | 145.39M | 159.83M | 186.69M |
| Common Stock | 25.93M | 30.52M | 39.82M | 158.02M | 317.65M | 313.46M | 332.08M | 343.64M | 358.54M | 368.56M |
| Retained Earnings | 73.66M | 68.28M | 73.3M | 71.93M | 72.46M | 76.67M | 74.2M | -183.49M | -188.94M | -180.73M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.76M | 564K | -1.81M | -9.94M | 16.12M | 3.67M | -12.79M | -14.76M | -9.78M | -1.14M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MLAB Cash Flow Statement
Mesa Laboratories, Inc. (MLAB) cash flow — operating, investing & free cash flow history
| Line item | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 7.75M | 24.81M | 30.55M | 26.56M | 37.07M | 39.22M | 27.98M | 44.13M | 46.81M | 46.81M |
| Operating CF Margin % | 8.27% | 25.8% | 29.63% | 22.57% | 27.68% | 21.28% | 12.77% | 20.41% | 19.42% | - |
| Operating CF Growth % | -54.15% | 220.18% | 23.13% | -13.08% | 39.59% | 5.8% | -28.66% | 57.71% | 6.06% | -25.85% |
| Net Income | 11.18M | -2.96M | 7.48M | 1.35M | 3.27M | 1.87M | 930K | -254.25M | -1.97M | 3.73M |
| Depreciation & Amortization | 8.74M | 9.47M | 9.43M | 12.99M | 17.66M | 25.07M | 33.13M | 31.57M | 24.53M | 25.02M |
| Stock-Based Compensation | 1.41M | 1.67M | 4.21M | 5.53M | 9.27M | 11.39M | 12.54M | 11.94M | 13.14M | 14.21M |
| Deferred Taxes | -630K | -2.7M | -2.47M | -1.97M | -3.5M | 128K | -3.49M | -28.42M | -72K | 0 |
| Other Non-Cash Items | 93K | 16.1M | 4.01M | 11.8M | 5.12M | 7.96M | 1.99M | 277.32M | 4.28M | -7.71M |
| Working Capital Changes | -13.04M | 3.24M | 7.89M | -3.14M | 5.25M | -7.19M | -17.11M | 5.97M | 6.9M | 6.27M |
| Change in Receivables | 994K | 680K | 1.59M | -1.67M | -647K | -6.75M | -2.12M | 4.94M | -2.92M | -2.1M |
| Change in Inventory | 295K | 2.29M | 2.57M | 414K | 929K | -1.04M | -10.18M | 2.56M | 1.15M | -1.77M |
| Change in Payables | -655K | 212K | 1.09M | -61K | 967K | 1.37M | -1.54M | -97K | -388K | 658K |
| Cash from Investing | -18.41M | -17.18M | -3.88M | -185.59M | -1.99M | -305.23M | -9.49M | -81.31M | -4.5M | -3.84M |
| Capital Expenditures | -11.61M | -2.8M | -1.26M | -1.5M | -1.99M | -4.43M | -4.54M | -2.57M | -4.25M | -3.59M |
| CapEx % of Revenue | 12.39% | 2.91% | 1.22% | 1.27% | 1.49% | 2.4% | 2.07% | 1.19% | 1.76% | - |
| Acquisitions | -6.8M | -15.52M | -4.84M | -184.1M | 0 | -300.79M | -4.95M | -78.74M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -6.8M | 1.13M | 2.22M | 15K | 0 | 0 | 0 | 0 | -250K | -250K |
| Cash from Financing | 10.71M | -8.12M | -21.67M | 231.28M | 146.23M | 52.58M | -33.33M | 32.84M | -44.51M | -42.29M |
| Debt Issued (Net) | 9.55M | -8.63M | -23.63M | 149.5M | 0 | 49M | -36M | 37.5M | -42.35M | -21.31M |
| Equity Issued (Net) | 1000K | 0 | 1000K | 1000K | 1000K | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | -2.35M | -2.41M | -2.46M | -2.72M | -3.17M | -3.34M | -3.41M | -3.45M | -3.47M | -3.51M |
| Share Repurchases | 0 | 0 | -5.09M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 2.92M | -680K | -5.44M | 3.46M | 6.92M | 6.08M | -1.22M | 1.3M | -17.47M |
| Net Change in Cash | 125K▲ 0% | -351K▼ 380.8% | 4.72M▲ 1443.6% | 71.19M▲ 1409.6% | 182.49M▲ 156.3% | -214.52M▼ 217.6% | -16.44M▲ 92.3% | -4.7M▲ 71.4% | -893K▲ 81.0% | -1.98M▲ 0% |
| Free Cash Flow | -3.85M▲ 0% | 22.02M▲ 671.1% | 29.29M▲ 33.1% | 25.06M▼ 14.4% | 35.08M▲ 40.0% | 34.79M▼ 0.8% | 23.44M▼ 32.6% | 41.57M▲ 77.3% | 42.31M▲ 1.8% | 37.69M▲ 0% |
| FCF Margin % | -4.12% | 22.89% | 28.4% | 21.29% | 26.19% | 18.87% | 10.7% | 19.23% | 17.56% | 15.23% |
| FCF Growth % | -142.02% | 671.08% | 33.05% | -14.44% | 39.98% | -0.83% | -32.63% | 77.34% | 1.79% | -12.34% |
| FCF per Share | -1.00 | 5.84 | 7.26 | 5.73 | 6.85 | 6.52 | 4.37 | 7.72 | 7.79 | 7.79 |
| FCF Conversion (FCF/Net Income) | 0.69x | -8.38x | 4.08x | 14.94x | 11.32x | 20.96x | 30.09x | -0.17x | -23.71x | 10.09x |
| Interest Paid | 1.38M | 1.96M | 1.64M | 1.63M | 2.37M | 2.76M | 3.48M | 4.65M | 11.08M | 0 |
| Taxes Paid | 5.61M | -4.55M | 5.87M | 2.63M | 1.37M | 3.05M | 1.36M | 4.59M | 5.73M | 0 |
MLAB Key Ratios
Mesa Laboratories, Inc. (MLAB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 12.26% | -3% | 7.1% | 1.07% | 1.05% | 0.47% | 0.24% | -94.36% | -1.29% | 2% |
| Return on Invested Capital (ROIC) | 9.03% | 1.14% | 5.56% | 2.94% | 3.26% | 0.83% | 0.45% | -45.59% | 3.7% | 3.7% |
| Gross Margin | 56.84% | 56.79% | 59.06% | 55.54% | 64.97% | 59.18% | 61.02% | 61.64% | 62.61% | 60.61% |
| Net Margin | 11.94% | -3.08% | 7.26% | 1.51% | 2.44% | 1.01% | 0.42% | -117.6% | -0.82% | 1.51% |
| Debt / Equity | 0.56x | 0.47x | 0.20x | 0.64x | 0.36x | 0.56x | 0.47x | 1.59x | 1.14x | 1.14x |
| Interest Coverage | - | 1.18x | - | 1.44x | 1.54x | 1.21x | 0.70x | -47.76x | 1.38x | 2.36x |
| FCF Conversion | 0.69x | -8.38x | 4.08x | 14.94x | 11.32x | 20.96x | 30.09x | -0.17x | -23.71x | 10.09x |
| Revenue Growth | 10.64% | 2.68% | 7.23% | 14.11% | 13.81% | 37.63% | 18.85% | -1.32% | 11.47% | 4.12% |
MLAB SEC Filings & Documents
Mesa Laboratories, Inc. (MLAB) SEC filings — annual & quarterly reports (10-K, 10-Q)
MLAB Frequently Asked Questions
Mesa Laboratories, Inc. (MLAB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Mesa Laboratories, Inc. (MLAB) reported $247.5M in revenue for fiscal year 2025. This represents a 2956% increase from $8.1M in 1996.
Mesa Laboratories, Inc. (MLAB) grew revenue by 11.5% over the past year. This is steady growth.
Yes, Mesa Laboratories, Inc. (MLAB) is profitable, generating $3.7M in net income for fiscal year 2025 (-0.8% net margin).
Dividend & Returns
Yes, Mesa Laboratories, Inc. (MLAB) pays a dividend with a yield of 0.60%. This makes it attractive for income-focused investors.
Mesa Laboratories, Inc. (MLAB) has a return on equity (ROE) of -1.3%. Negative ROE indicates the company is unprofitable.
Mesa Laboratories, Inc. (MLAB) generated $37.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More MLAB
Mesa Laboratories, Inc. (MLAB) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates